Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(NasdaqGM:ZNTL), SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Zentalis(R) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to […]